Just to clarify, I think what you're referring to is that in the PMPRB report they break down that total R and D spent. Of the $1.2 billion, they categorize it as “discovery”, “applied”, and “other”. I think the issue is the discovery component, that $232 million, which represents about 20%. Is that enough?
If you look globally at the allocation of the total cost, because there's not only the discovery, there are various steps--you have the discovery, and then you have the development, and then you have the approval of the drug.... I've been trying to find the latest statistics, but historically the drug discovery component usually runs at around 25% to 30% of those total costs. There are various steps involved in that, where you identify a disease, where you identify potential candidates, where you do some safety testing. Then if you have candidates that it appears are going to be safe and work for a condition, you then start the development process. That development process is where you try it in patients who have the disease, you try it then in healthy patients, and that's where the cost starts to grow significantly. So the fact that it's $232 million is probably maybe a little on the low side, but not that far off what it is globally.
Certainly at our facility in Montreal the majority of our $120 million is in what you'd call the basic research, but you still have to have the development component as well before you can get a drug on the market.